JaLCDOI 10.18926/AMO/55446
FullText URL 71_5_453.pdf
Author Taniguchi, Akihiko| Miyahara, Nobuaki| Oda, Naohiro| Morichika, Daisuke| Ichihara, Eiki| Oze, Isao| Tanimoto, Yasushi| Ichikawa, Hirohisa| Fujii, Utako| Tanimoto, Mitsune| Kanehiro, Arihiko| Kiura, Katsuyuki|
Abstract Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure.
Keywords chronic obstructive pulmonary disease β-blocker bisoprolol exacerbation heart failure
Amo Type Clinical Study Protocol
Published Date 2017-10
Publication Title Acta Medica Okayama
Volume volume71
Issue issue5
Publisher Okayama University Medical School
Start Page 453
End Page 457
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29042706
JaLCDOI 10.18926/AMO/54514
FullText URL 70_4_327.pdf
Author Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi|
Abstract A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8+ T cells, which produce multiple cytokines.
Keywords metformin CD8+ T cells cancer immunology
Amo Type Clinical Study Protocols
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 327
End Page 330
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549683
Web of Sience KeyUT 000384748600018
JaLCDOI 10.18926/AMO/54503
FullText URL 70_4_273.pdf
Author Makimoto, Go| Miyahara, Nobuaki| Yoshikawa, Mao| Taniguchi, Akihiko| Kanehiro, Arihiko| Tanimoto, Mitsune| Kiura, Katsuyuki|
Abstract Heerfordtʼs syndrome is a rare manifestation of sarcoidosis and is defined as a combination of facial palsy, parotid swelling, and uveitis, associated with a low-grade fever. We report a case of Heerfordtʼs syndrome presenting with a high fever and increased serum tumor necrosis factor alpha (TNF-α) levels. The patient had facial palsy, parotid swelling, uveitis, and swelling of the right supraclavicular and hilar lymph nodes. Corticosteroid therapy was initiated, and her symptoms soon resolved completely, in tandem with a decrease in TNF-α serum levels.
Keywords Heerfordtʼs syndrome sarcoidosis TNF-α
Amo Type Case Report
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 273
End Page 277
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549672
Web of Sience KeyUT 000384748600007
JaLCDOI 10.18926/AMO/54499
FullText URL 70_4_243.pdf
Author Osawa, Masahiro| Ohashi, Kadoaki| Kubo, Toshio| Ichihara, Eiki| Takata, Saburo| Takigawa, Nagio| Takata , Minoru| Tanimoto, Mitsune| Kiura, Katsuyuki|
Abstract Vandetanib (ZactimaTM) is a novel, orally available inhibitor of both vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase. In the present study, a line of transgenic mice with a mouse Egfr gene mutation (delE748-A752) corresponding to a human EGFR mutation (delE746-A750) was established. The transgenic mice developed atypical adenomatous hyperplasia to adenocarcinoma of the lung at around 5 weeks of age and died of lung tumors at approximately 17 weeks of age. In the mice treated with vandetanib (6mg/kg/day), these lung tumors disappeared and the phosphorylations of EGFR and VEGFR-2 were reduced in lung tissues to levels comparable to those of non-transgenic control mice. The median overall survival time of the transgenic mice was 28 weeks in the vandetanib-treated group and 17 weeks in the vehicle-treated group. Vandetanib significantly prolonged the survival of the transgenic mice (log-rank test, p<0.01); resistance to vandetanib occurred at 20 weeks of age and the animals died from their lung tumors at about 28 weeks of age. These data suggest that vandetanib could suppress the progression of tumors harboring an activating EGFR mutation.
Keywords vandetanib VEGFR EGFR nonsmall cell lung cancer transgenic mouse
Amo Type Original Article
Published Date 2016-08
Publication Title Acta Medica Okayama
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 243
End Page 253
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549668
Web of Sience KeyUT 000384748600003
JaLCDOI 10.18926/AMO/53671
FullText URL 69_5_261.pdf
Author Nojima, Daisuke| Fujimoto, Nobukazu| Kato, Katsuya| Fuchimoto, Yasuko| Kiura, Katsuyuki| Kishimoto, Takumi| Tanimoto, Mitsune|
Abstract We investigated the clinical features of asbestos-induced diffuse pleural thickening (DPT) with severe respiratory compromise. We conducted a retrospective study of consecutive subjects with asbestos-induced DPT. Medical data such as initial symptoms, radiological findings, respiratory function test results, and clinical course were collected and analyzed. There were 24 patients between 2003 and 2012. All were men, and the median age at the development of DPT was 74 years. The top occupational category associated with asbestos exposure was dockyard workers. The median duration of asbestos exposure was 35.0 years, and the median latency from first exposure to the onset of DPT was 49.0 years. There were no significant differences in respiratory function test results between the higher and lower Brinkman index groups or between unilateral and bilateral DPT. Thirteen patients had a history of benign asbestos pleural effusion (BAPE), and the median duration from pleural fluid accumulation to DPT with severe respiratory compromise was 28.4 months. DPT with severe respiratory compromise can develop after a long latency following occupational asbestos exposure and a history of BAPE.
Keywords asbestos pleural thickening MRC dyspnea scale respiratory function test costophrenic angle
Amo Type Original Article
Published Date 2015-10
Publication Title Acta Medica Okayama
Volume volume69
Issue issue5
Publisher Okayama University Medical School
Start Page 261
End Page 266
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26490022
Web of Sience KeyUT 000365519600001
Title Alternative A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy
FullText URL 127_127.pdf
Author Kiura, Katsuyuki| Hotta, Katsuyuki| Sato, Akiko| Ohashi, Kadoaki| Ninomiya, Takashi| Minnami, Daisuke| Tabata, Masahiro| Kubo, Toshio| Kato, Yuka| Hirata, Taizo|
Keywords 臨床研究中核病院 国立研究開発法人日本医療研究開発機構 文部科学省橋渡し研究加速ネットワークプログラム HER2-CS study trastuzumab emtansine
Publication Title 岡山医学会雑誌
Published Date 2015-08-03
Volume volume127
Issue issue2
Start Page 127
End Page 132
ISSN 0030-1558
Related Url isVersionOf https://doi.org/10.4044/joma.127.127
language 日本語
Copyright Holders Copyright (c) 2015 岡山医学会
File Version publisher
DOI 10.4044/joma.127.127
NAID 130005096256
Author Yasugi, Masayuki| Takigawa, Nagio| Ochi, Nobuaki| Ohashi, Kadoaki| Harada, Daijiro| Ninomiya, Takashi| Murakami, Toshi| Honda, Yoshihiro| Ichihara, Eiki| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2014-08-15
Publication Title Experimental Cell Research
Volume volume326
Issue issue2
Content Type Journal Article
Author Ochi, Nobuaki| Takigawa, Nagio| Harada, Daijiro| Yasugi, Masayuki| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2014-03-10
Publication Title Experimental Cell Research
Volume volume322
Issue issue1
Content Type Journal Article
Author Murakami, Toshi| Takigawa, Nagio| Ninomiya, Takashi| Ochi, Nobuaki| Yasugi, Masaaki| Honda, Yoshihiro| Kubo, Toshio| Ichihara, Eiki| Hotta, Katsuyuki| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2014-01
Publication Title Lung Cancer
Volume volume83
Issue issue1
Content Type Journal Article
Author Hayakawa, Hiromi| Ichihara, Eiki| Ohashi, Kadoaki| Ninomiya, Takashi| Yasugi, Masayuki| Takata, Saburo| Sakai, Katsuya| Matsumoto, Kunio| Takigawa, Nagio| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2013-11
Publication Title Cancer Science
Volume volume104
Issue issue11
Content Type Journal Article
Title Alternative Treatment for a non-compliant patient with cancer and epilepsy
FullText URL 126_133.pdf
Author Minami, Daisuke| Ichihara, Eiki| Okabe, Nobuyuki| Yokomichi, Naosuke| Kouge, Noriko| Kajizono, Makoto| Akimoto, Yutaka| Hori, Keisuke| Matsubara, Minoru| Nasu, Junichiro| Tanimoto, Mitsune| Kiura, Katsuyuki| Matsuoka, Junzi|
Abstract  A 58-year-old man with cervical esophageal cancer and a history of epilepsy was treated with chemoradiotherapy from May of 2013. When tube feeding was initiated due to aspiration pneumonitis, the patient showed a degree of irritability that affected routine staff work and treatment compliance. We attempted to perform supportive care for maladjustment by the notice, the fast, and the tube feeding, but there was no improvement. After we added carbamazepine, primidone, and propericiazine (which had been canceled at the initiation of the tube feeding) to the patient's intravenous phenytoin, the symptoms and treatment compliance improved significantly. We concluded that the causes of the patient's irritability were maladjustment and his epilepsy.
Keywords てんかん(epilepsy) 易怒性(irritability) 適応障害(maladjustment)
Publication Title 岡山医学会雑誌
Published Date 2014-08-01
Volume volume126
Issue issue2
Start Page 133
End Page 135
ISSN 0030-1558
language 日本語
Copyright Holders Copyright (c) 2014 岡山医学会
File Version publisher
DOI 10.4044/joma.126.133
NAID 130004685264
Author Ninomiya, Takashi| Takigawa, Nagio| Ichihara, Eiki| Ochi, Nobuaki| Murakami, Toshi| Honda, Yoshihiro| Kubo, Toshio| Minami, Daisuke| Kudo, Kenichiro| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2013-05
Publication Title Molecular Cancer Therapeutics
Volume volume12
Issue issue5
Content Type Journal Article
Author Takeda, Hiromasa| Takigawa, Nagio| Ohashi, Kadoaki| Minami, Daisuke| Kataoka, Itaru| Ichihara, Eiki| Ochi, Nobuaki| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2013-02-15
Publication Title Experimental Cell Research
Volume volume319
Issue issue4
Content Type Journal Article
Author Kiura, Katsuyuki|
Published Date 2013-08-01
Publication Title 岡山医学会雑誌
Volume volume125
Issue issue2
Content Type Journal Article
Author Ueno, Tsuyoshi| Tsukuda, Kazunori| Toyooka, Shinichi| Ando, Midori| Takaoka, Munenori| Soh, Junichi| Asano, Hiroaki| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Shien, Kazuhiko| Furukawa, Masashi| Yamatsuji, Tomoki| Kiura, Katsuyuki| Naomoto, Yoshio| Miyoshi, Shinichiro|
Published Date 2012-04
Publication Title Lung Cancer
Volume volume76
Issue issue1
Content Type Journal Article
Author Shien, Kazuhiko| Toyooka, Shinichi| Ichimura, Kouichi| Soh, Junichi| Furukawa, Masashi| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Ueno, Tsuyoshi| Asano, Hiroaki| Tsukuda, Kazunori| Yamane, Masaomi| Oto, Takahiro| Kiura, Katsuyuki| Miyoshi, Shinichiro|
Published Date 2012-07
Publication Title Lung Cancer
Volume volume77
Issue issue1
Content Type Journal Article
Author Harada, Daijiro| Takigawa, Nagio| Ochi, Nobuaki| Ninomiya, Takashi| Yasugi, Masayuki| Kubo, Toshio| Takeda, Hiromasa| Ichihara, Eiki| Ohashi, Kadoaki| Takata, Saburo| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2012-10
Publication Title Cancer Science
Volume volume103
Issue issue10
Content Type Journal Article
Author Kubo, Toshio| Takigawa, Nagio| Osawa, Masahiro| Harada, Daijiro| Ninomiya, Takashi| Ochi, Nobuaki| Ichihara, Eiki| Yamane, Hiromichi| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2013-01
Publication Title Cancer Science
Volume volume104
Issue issue1
Content Type Journal Article
Author Rai, Kammei| Takigawa, Nagio| Ito, Sachio| Kashihara, Hiromi| Ichihara, Eiki| Yasuda, Tatsuji| Shimizu, Kenji| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2011-09
Publication Title Molecular Cancer Therapeutics
Volume volume10
Issue issue9
Content Type Journal Article
Author Kiura, Katsuyuki| Tanimoto, Mitsune|
Published Date 2013-04-01
Publication Title 岡山医学会雑誌
Volume volume125
Issue issue1
Content Type Journal Article